Reumatismo Palindrómico
Resumen
El Reumatismo palindrómico (RP) se caracteriza por episodios de artritis recurrente, generalmente monoarticular, de duración promedio 24-48 horas. Un número significativo de casos evoluciona a una enfermedad reumática crónica, en especial a una artritis reumatoide (AR). Existe una controversia en relación a si el RP es una entidad por sí misma o una forma abortiva o preclínica de AR. Se ha demostrado la elevada frecuencia de anticuerpos anti peptidos cíclicos citrulinados (ACPA), los biomarcadores más específicos de la AR, en pacientes con RP, lo que fortalece aún más el vínculo con la AR. Además, aunque el fator reumatoide y los ACPA positivos son factores predictores de progresión de RP a AR, un número significativo de pacientes no evoluciona a AR después de un seguimiento a largo plazo. Por este motivo existe un renovado interés en la determinación de los factores de riesgo a fin de determinar que pacientes evolucionarán y cuáles no, lo que tendría implicancias importantes en la práctica clínica, pues dichos pacientes necesitarán sin duda un seguimiento más estrecho y una estrategia terapéutica más precoz y diferenciada. En esta revisión se analizan exhaustivamente los aspectos epidemiológicos, clínicos, diagnósticos, pronósticos y terapéuticos del RP.Descargas
Citas
(1) Hench PS, Rosenberg EF. Palindromic Rheumatism. A new oftrecurring disease of joints (arthritis, peri-arthritis) apparently producing no articular residues. Report of thirty-four cases, its relationship to „angioneural arthrosis“, allergic rheumatism“ and rheumatoid arthritis. Arch Inter Med. 1944;73:293-321.
(2) Pasero G, Barbieri P. Palindromic rheumatism: you just have to think about it! Clin Exp Rheumatol 1986;4(3):197-9.
(3) Powell A, Davis P, Jones N, Russell AS. Palindromic rheumatism is a common disease: comparison of new-onset palindromic rheumatism compared to new-onset rheumatoid arthritis in a 2-year cohort of patients. J Rheumatol 2008;35(6):992-4.
(4) Sanmarti R, Cabrera-Villalba S, Gomez-Puerta JA, Ruiz-Esquide V, Hernandez MV, Salvador G, et al. Palindromic rheumatism with positive anticitrullinated peptide/protein antibodies is not synonymous with rheumatoid arthritis. A longterm followup study. J Rheumatol 2012;39(10):1929-33.
(5) Guerne PA, Weisman MH. Palindromic rheumatism: part of or apart from the spectrum of rheumatoid arthritis. Am J Med 1992;93(4): 451-60.
(6) Wajed MA, Brown DL, Currey HL. Palindromic rheumatism. Clinical and serum complement study. Ann Rheum Dis 1977;36(1):56-61.
(7) T hompson B, Mohammed I, Holborow EJ, Currey HL. Palindromic rheumatism. Failure to detect circulating immune complexes during acute episodes. Ann Rheum Dis 1979;38(4):329-31.
(8) Fisher LR, Kirk A, Awad J, Festenstein H, Alonso A, Perry JD, et al. HLA antigens in palindromic rheumatism and palindromic onset rheumatoid arthritis. Br J Rheumatol 1986;25(4):345-8.
(9) Gran JT, Husby G, Thorsby E. HLA antigens in palindromic rheumatism, nonerosive rheumatoid arthritis and classical rheumatoid arthritis. J Rheumatol 1984;11(2):136-40.
(10) Barbieri P, Ciompi ML, Menicucci A, Pasero G. HLA antigens in palindromic rheumatism. An Italian study. Clin Rheumatol 1988;7(4):470-3.
(11) Bregeon C, Dajon JL, Renier G, Jegoude-Mauco F, Galland F, Fallah N, et al. Palindromic rheumatism. Immunologic survey and study of development in 43 cases. Rev Rhum Mal Osteoartic 1986;53(7-9):441-9.
(12) Maksymowych WP, Suarez-Almazor ME, Buenviaje H, Cooper BL, Degeus C, Thompson M, et al. HLA and cytokine gene polymorphisms in relation to occurrence of palindromic rheumatism and its progression to rheumatoid arthritis. J Rheumatol 2002;29(11): 2319-26.
(13) Kim SK, Lee HS, Lee KW, Bae SC, Jun JB. Palindromic rheumatism: different genetic background implies a distinct disease entity. Ann Rheum Dis 2006;65(11):1539-40.
(14) Lu LY, Keng HM, Chu JJ, Lin XT, Hsu CM, Sung PK. TNF receptor I polymorphism is associated with persistent palindromic rheumatism. Scand J Rheumatol 2007;36(4):278-84.
(15) C anete JD, Arostegui JI, Queiro R, Gratacos J, Hernandez MV, Larrosa M, et al. An unexpectedly high frequency of MEFV mutations in patients with anti-citrullinated protein antibody-negative palindromic rheumatism. Arthritis Rheum 2007;56(8):2784-8.
(16) R otés Querol J, Lience E. Reumatismo Palindromico. Rev Esp R eum Enferm Osteoartic 1967;1:42-7.
(17) Gonzalez-Lopez L, Gamez-Nava JI, Jhangri GS, Ramos-Remus C, R ussell AS, Suarez-Almazor ME. Prognostic factors for the development of rheumatoid arthritis and other connective tissue diseases in patients with palindromic rheumatism. J Rheumatol 1999;26(3):540-5.
(18) Hannonen P, Mottonen T, Oka M. Palindromic rheumatism. A clinical survey of sixty patients. Scand J Rheumatol 1987;16(6):413-20.
(19) Hardo HG. Palindromic rheumatism: a review. J R Soc Med 1981;74(7):521-4.
(20) Mattingly S. Palindromic rheumatism. Ann Rheum Dis 1966;25(4):307-17.
(21) Khabbazi A, Hajialiloo M, Kolahi S, Soroosh M, Esalatmanesh K, Sharif S. A multicenter study of clinical and laboratory findings of palindromic rheumatism in Iran. Int J Rheum Dis 2012;15(4): 427-30.
(22) Sanmarti R, Canete JD, Salvador G. Palindromic rheumatism and other relapsing arthritis. Best Pract Res Clin Rheumatol 2004;18(5): 647-61.
(23) Gonzalez-Lopez L, Gamez-Nava JI, Jhangri G, Russell AS, Suarez-Almazor ME. Decreased progression to rheumatoid arthritis or other connective tissue diseases in patients with palindromic rheumatism treated with antimalarials. J Rheumatol 2000;27(1):41-6.
(24) R ussell AS, Devani A, Maksymowych WP. The role of anti-cyclic citrullinated peptide antibodies in predicting progression of palindromic rheumatism to rheumatoid arthritis. J Rheumatol 2006;33(7):1240-2.
(25) C abrera- Villalba S, Ramirez J, Salvador G, Ruiz-Esquide V, Hernández M.V, Inciarte-Mundo J, et al. Is there subclinical synovitis in patients with palindromic rheumatism in the intercritical period? A clinical and ultrasonographic study according to anticitrullinated peptide/protein antibody status. J Rheum 2014;
(8):1650.
(26) C abrera-Villalba S, Sanmarti R. Palindromic Rheumatism: a reappraisal.
Int. J. Clin. Rheumatol. 2013;8(5):569-77.
(27) C hen HH, Lan JL, Hung GD, Chen YM, Lan HH, Chen DY. As sociation of ultrasonographic findings of synovitis with anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with palindromic rheumatism during active episodes. J Ultrasound Med 2009;28(9):1193-9.
(28) Ueda S, Horino T, Arii K, Morita T, Takao T, Hashimoto K. Magnetic resonance imaging of palindromic rheumatism. Rheumatol Int 2008;29(1):87-9.
(29) Koskinen E, Hannonen P, Sokka T. Palindromic rheumatism: longterm outcomes of 60 patients diagnosed in 1967-84. J Rheumatol 2009;36(9):1873-5.
(30) C aroit M, de Seze S. [A case of palindromic rheumatism which developed into psoriatic rheumatism]. Rev Rhum Mal Osteoartic 1966;33(5):272-3.
(31) Emad Y, Anbar A, Abo-Elyoun I, El-Shaarawy N, Al-Hanafi H, Darwish H, et al. In palindromic rheumatism, hand joint involvement and positive anti-CCP antibodies predict RA development after 1 year of follow-up. Clin Rheumatol 2014.
(32) E liakim A, Neumann L, Horowitz J, Buskila D, Kleiner-Baumgarten A, Sukenik S. Palindromic rheumatism in Israel a disease entity? A survey of 34 patients. Clin Rheumatol 1989;8(4):507-11.
(33) Finn BC, Young P, Laborde H, Earsman G, Noe DD, Barreira JC, et al. Palindromic rheumatism. Report of one case. Rev Med Chil 2010;138(7):852-5.
(34) Hanonen P, Mottonen T, Oka M. Treatment of palindromic rheumatism with chloroquine. Br Med J (Clin Res Ed) 1987;294(6582):1289.
(35) Youssef W, Yan A, Russell AS. Palindromic rheumatism: a response to chloroquine. J Rheumatol 1991;18(1):35-7.
